References
- Falini B, Lenze D, Hasserjian R, et al Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia 2007;21:1566–1570.
- Pileri S, Ascani S, Cox M, et al Myeloid sarcoma: clinico-pathologic, phenotypic, and cytogenetic analysis of 92 adult patients. Leukemia 2007;21:340–350.
- Andersen MT, Andersen MK, Christiansen DH, et al NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features. Leukemia 2008;22:951–955.
- Falini B, Nicoletti I, Massimo F, et al Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML); biologic and clinical features. Blood 2007;109:874–885.
- Schnittger S, Schoch C, Kern W, et al Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733–3739.
- Swerdlow S, Campo E, Harris L, et al WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
- Thiede C, Koch S, Creutzig E, et al Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia. Blood 2006;107:4011–4020.